N-tert-butyloxycarbonyl-N-(1,1-dimethyl-2-propenyl)amine | 91230-08-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-tert-butyloxycarbonyl-N-(1,1-dimethyl-2-propenyl)amine
• 英文别名: tert-butyl (2-methylbut-3-en-2-yl)carbamate；(1,1-dimethyl-allyl)-carbamic acid tert-butyl ester；(1,1-Dimethylallyl)carbamic acid tert-butyl ester；tert-butyl N-(2-methylbut-3-en-2-yl)carbamate
• CAS: 91230-08-9
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: MQXYPUXSBGLOKY-UHFFFAOYSA-N

物化性质

• 沸点：
  245.3±19.0 °C(Predicted)
• 密度：
  0.921±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-tert-butyloxycarbonyl-N-(1,1-dimethyl-2-propenyl)amine 在 过氧化双月桂酰 、 乙二胺 作用下， 以 乙醇 、 环己烷 为溶剂， 生成 [2-Mercapto-5-(4-methoxy-phenyl)-1,1-dimethyl-5-oxo-pentyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  对哌啶，吡啶，氮杂和相关衍生物的灵活收敛方法

  摘要：

  已经开发出一种高度收敛的方法来构建各种氮杂环，该方法使用将α-酮基的分子间加成到适当保护的烯丙基或均烯丙基胺上作为关键步骤。

  DOI：

  10.1016/s0040-4039(99)00592-4
• 作为产物：
  描述：

  N-重氮基氨基甲酸叔-丁基酯 在 三乙胺 、 iron(II) chloride 、 亚磷酸三乙酯 作用下， 以 二氯甲烷 为溶剂， 反应 3.5h， 生成 N-tert-butyloxycarbonyl-N-(1,1-dimethyl-2-propenyl)amine
  参考文献：
  名称：

  Fe(II)-Catalyzed Imidation of Allyl Sulfides and Subsequent [2,3]-Sigmatropic Rearrangement. Preparation of α-Branched N-tert-Butyloxycarbonyl (Boc)-Protected N-Allylamines

  摘要：

  Allyl aryl sulfides 1 and 5 were shown to undergo an imidation/[2,3]-sigmatropic rearrangement reaction upon treatment with N-tert-butyloxycarbonyl azide (BocN(3)) and catalytic amounts of FeCl2 in CH2Cl2. The N-Boc-protected N-allyl sulfenamides 3 and 21 were obtained in yields between 48 and 75% (12 examples), Whereas the reaction is well suited for the transformation of alpha-unbranched sulfides to a-branched sulfenamides, the enantiomerically pure alpha-branched sulfides 10 and 13 reacted sluggishly. The corresponding sulfenamides 22 and 23 were obtained in only moderate enantiomeric excess (36-39% eel. A reaction mechanism is proposed that postulates the intermediacy of an N-Boc-substituted Fe(IV)-nitrene complex 14 acting as the imidation reagent in the catalytic cycle. Possible side reactions are discussed. The benzenesulfenamides 3 were further converted into N-Boc-N-allylamines 4 by removal of the phenylsulfanyl group. Bu3SnH in benzene was found to be the reagent of choice for the deprotection of alpha-branched amines that bear a secondary allyl substituent (five examples, 71-93% yield). This method failed for the alpha-branched amines 3i-k with a tertiary allyl substituent. The phenylsulfanyl group was finally removed with P(OEt)(3)/NEt3 in CH2Cl2 (three examples, 43-62% yield).

  DOI：

  10.1021/jo991569p

文献信息

• [EN] MACROCYCLES AS PIM INHIBITORS<br/>[FR] MACROCYCLES EN TANT QU'INHIBITEURS DE PIM
  申请人：AMGEN INC

  公开号：WO2014022752A1

  公开（公告）日：2014-02-06

  The invention relates to compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及式（1）的化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2以及/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文所披露的化合物的药物组合物，以及它们在预防和治疗与Pim激酶相关的疾病和病症，尤其是癌症中的用途。
• [EN] AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS<br/>[FR] COMPOSÉS AMINOPYRIMIDINES EN TANT QU'INHIBITEURS DE MUTANTS D'EGFR CONTENANT T790M
  申请人：GENENTECH INC

  公开号：WO2014081718A1

  公开（公告）日：2014-05-30

  This invention relates to novel compounds of formula (I) which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer. (Formula I)

  这项发明涉及公式（I）的新化合物，这些化合物是T790M含有EGFR突变体的抑制剂，涉及含有它们的药物组合物，它们的制备方法，以及它们在预防或治疗癌症中的应用。
• [EN] ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS<br/>[FR] ANALOGUES D'AMINOGLYCOSIDES ANTIBACTÉRIENS
  申请人：ACHAOGEN INC

  公开号：WO2009067692A1

  公开（公告）日：2009-05-28

  Compounds of structure (I): having antibacterial activity are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  结构（I）的化合物具有抗菌活性，包括立体异构体、药用可接受的盐和前药，其中Q1、Q2、Q3、R8和R9如本文所定义。还公开了与制备和使用这些化合物相关的方法，以及包含这些化合物的药物组合物。
• Organic compounds
  申请人：Novartis AG

  公开号：US08084448B2

  公开（公告）日：2011-12-27

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式为的化合物是蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖耐受性、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗，以及伴随2型糖尿病的情况，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常和其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、肌肉骨骼、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS
  申请人：Bryan Marian C.

  公开号：US20160016948A1

  公开（公告）日：2016-01-21

  This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

  本发明涉及一种新型化合物，它们是T790M含有EGFR突变体的抑制剂，包括含有它们的制药组合物、它们的制备过程以及它们在预防或治疗癌症的治疗中的使用。